Mereo Biopharma Group Stock Performance
| MREO Stock | USD 3.61 0.05 1.40% |
The company secures a Beta (Market Risk) of 1.13, which conveys a somewhat significant risk relative to the market. Mereo BioPharma returns are very sensitive to returns on the market. As the market goes up or down, Mereo BioPharma is expected to follow. At this point, Mereo BioPharma Group has a negative expected return of -0.26%. Please make sure to verify Mereo BioPharma's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Mereo BioPharma Group performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 1.26 | Five Day Return (3.09) | Year To Date Return 56.74 | Ten Year Return (44.54) | All Time Return (44.54) |
1 | Disposition of 75000 shares by Hughes-wilson Alexandra of Mereo BioPharma at 1.01 subject to Rule 16b-3 | 09/11/2024 |
2 | Disposition of 40029 shares by Hughes-wilson Alexandra of Mereo BioPharma at 4.4727 subject to Rule 16b-3 | 09/12/2024 |
3 | Disposition of 84008 shares by Hughes-wilson Alexandra of Mereo BioPharma at 4.221 subject to Rule 16b-3 | 09/13/2024 |
4 | Mereo BioPharmas chief scientific officer sells shares worth over 69,000 | 09/17/2024 |
5 | Mereo BioPharma Group plc CEO Denise Scots-Knight Sells 28,611 Shares | 09/19/2024 |
6 | Integral Health Asset Management LLC Has 6. Million Stock Holdings in Mereo BioPharma Group plc - MarketBeat | 09/23/2024 |
7 | Acquisition by Fox Christine Ann of 245000 shares of Mereo BioPharma at 3.36 subject to Rule 16b-3 | 09/27/2024 |
8 | Perceptive Advisors LLC Invests 4.51 Million in Mereo BioPharma Group plc - MarketBeat | 09/30/2024 |
9 | Acquisition by Hughes-wilson Alexandra of 93333 shares of Mereo BioPharma at 1.4 subject to Rule 16b-3 | 11/11/2024 |
10 | Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/12/2024 |
11 | Janus Henderson Group PLCs Strategic Acquisition in Mereo BioPharma Group PLC | 11/14/2024 |
12 | HealthInvest Partners AB Invests 822,000 in Mereo BioPharma Group plc | 11/21/2024 |
| Begin Period Cash Flow | 68.2 M |
Mereo |
Mereo BioPharma Relative Risk vs. Return Landscape
If you would invest 443.00 in Mereo BioPharma Group on September 1, 2024 and sell it today you would lose (82.00) from holding Mereo BioPharma Group or give up 18.51% of portfolio value over 90 days. Mereo BioPharma Group is currently does not generate positive expected returns and assumes 3.5943% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Mereo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mereo BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mereo BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mereo BioPharma Group, and traders can use it to determine the average amount a Mereo BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0721
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MREO |
Estimated Market Risk
| 3.59 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mereo BioPharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mereo BioPharma by adding Mereo BioPharma to a well-diversified portfolio.
Mereo BioPharma Fundamentals Growth
Mereo Stock prices reflect investors' perceptions of the future prospects and financial health of Mereo BioPharma, and Mereo BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mereo Stock performance.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (37.90) % | ||||
| Current Valuation | 478.48 M | ||||
| Shares Outstanding | 153.85 M | ||||
| Price To Earning | 6.73 X | ||||
| Price To Book | 7.61 X | ||||
| Price To Sales | 559.30 X | ||||
| Revenue | 10 M | ||||
| Gross Profit | 936 K | ||||
| EBITDA | (26.06 M) | ||||
| Net Income | (29.47 M) | ||||
| Cash And Equivalents | 94.3 M | ||||
| Cash Per Share | 0.81 X | ||||
| Total Debt | 5.95 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 7.92 X | ||||
| Book Value Per Share | 0.51 X | ||||
| Cash Flow From Operations | (21.13 M) | ||||
| Earnings Per Share | (0.25) X | ||||
| Market Capitalization | 630.8 M | ||||
| Total Asset | 66.5 M | ||||
| Retained Earnings | (419.63 M) | ||||
| Working Capital | 54.27 M | ||||
| Current Asset | 94 K | ||||
| Current Liabilities | 729 K | ||||
About Mereo BioPharma Performance
By examining Mereo BioPharma's fundamental ratios, stakeholders can obtain critical insights into Mereo BioPharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Mereo BioPharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.2 K | -1.1 K | |
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.50) | (0.52) | |
| Return On Assets | (0.44) | (0.47) | |
| Return On Equity | (0.58) | (0.55) |
Things to note about Mereo BioPharma Group performance evaluation
Checking the ongoing alerts about Mereo BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mereo BioPharma Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mereo BioPharma generated a negative expected return over the last 90 days | |
| Mereo BioPharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 10 M. Net Loss for the year was (29.47 M) with profit before overhead, payroll, taxes, and interest of 936 K. | |
| Mereo BioPharma Group currently holds about 94.3 M in cash with (21.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81. | |
| Mereo BioPharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: HealthInvest Partners AB Invests 822,000 in Mereo BioPharma Group plc |
- Analyzing Mereo BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mereo BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Mereo BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mereo BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mereo BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mereo BioPharma's stock. These opinions can provide insight into Mereo BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.